Costanza L Vallerga
Overview
Explore the profile of Costanza L Vallerga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1516
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beran M, Jansen W, Oomens J, Moonen J, Slagboom P, Huisman M, et al.
Alzheimers Dement
. 2024 Oct;
20(12):8402-8411.
PMID: 39428719
Introduction: This study assessed the association of plasma biomarkers of endothelial dysfunction with cognitive performance and decline. Methods: Data from 9414 individuals from eight Dutch cohorts were included (Ø age-range:...
2.
Kuiper L, Polinder-Bos H, Bizzarri D, Vojinovic D, Vallerga C, Beekman M, et al.
J Gerontol A Biol Sci Med Sci
. 2023 Jun;
78(10):1753-1762.
PMID: 37303208
Biological age captures a person's age-related risk of unfavorable outcomes using biophysiological information. Multivariate biological age measures include frailty scores and molecular biomarkers. These measures are often studied in isolation,...
3.
Abozaid Y, Ayada I, van Kleef L, Vallerga C, Pan Q, Brouwer W, et al.
Hepatology
. 2023 Feb;
78(1):284-294.
PMID: 36738080
Background And Aims: Fatty liver disease (FLD) is caused by excess fat in the liver, and its global prevalence exceeds 33%. The role of protein expression on the pathogenesis of...
4.
Szilagyi I, Vallerga C, Boer C, Schiphof D, Ikram M, Bierma-Zeinstra S, et al.
Rheumatology (Oxford)
. 2022 Aug;
62(3):1286-1295.
PMID: 35924962
Objectives: The aim of this study was to identify biomarkers for radiographic OA severity and progression acting within the inflammation and metabolic pathways. Methods: For 3517 Rotterdam Study participants, 184...
5.
Nabais M, Laws S, Lin T, Vallerga C, Armstrong N, Blair I, et al.
Genome Biol
. 2021 Mar;
22(1):90.
PMID: 33771206
Background: People with neurodegenerative disorders show diverse clinical syndromes, genetic heterogeneity, and distinct brain pathological changes, but studies report overlap between these features. DNA methylation (DNAm) provides a way to...
6.
Gosselt H, Vallerga C, Mandaviya P, Lubberts E, Hazes J, de Jonge R, et al.
PLoS One
. 2021 Mar;
16(3):e0247709.
PMID: 33690661
Aim: To identify differentially methylated positions (DMPs) and regions (DMRs) that predict response to Methotrexate (MTX) in early rheumatoid arthritis (RA) patients. Materials And Methods: DNA from baseline peripheral blood...
7.
Vallerga C, Zhang F, Fowdar J, McRae A, Qi T, Nabais M, et al.
Nat Commun
. 2020 Mar;
11(1):1238.
PMID: 32144264
An improved understanding of etiological mechanisms in Parkinson's disease (PD) is urgently needed because the number of affected individuals is projected to increase rapidly as populations age. We present results...
8.
Nabais M, Lin T, Benyamin B, Williams K, Garton F, Vinkhuyzen A, et al.
NPJ Genom Med
. 2020 Mar;
5:10.
PMID: 32140259
We conducted DNA methylation association analyses using Illumina 450K data from whole blood for an Australian amyotrophic lateral sclerosis (ALS) case-control cohort (782 cases and 613 controls). Analyses used mixed...
9.
Nalls M, Blauwendraat C, Vallerga C, Heilbron K, Bandres-Ciga S, Chang D, et al.
Lancet Neurol
. 2019 Nov;
18(12):1091-1102.
PMID: 31701892
Background: Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of...
10.
Zhang Q, Vallerga C, Walker R, Lin T, Henders A, Montgomery G, et al.
Genome Med
. 2019 Aug;
11(1):54.
PMID: 31443728
Background: DNA methylation changes with age. Chronological age predictors built from DNA methylation are termed 'epigenetic clocks'. The deviation of predicted age from the actual age ('age acceleration residual', AAR)...